(February 14, 2023, 11:10 AM EST) -- ALEXANDRIA, Va. — In a Feb. 13 petition for inter partes review (IPR), a drug company seeks cancellation of various claims of a patented method of treating prostate cancers involving prostate-specific membrane antigen (PSMA) overexpression....